The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
about
Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic childrenFrom the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinaseEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatmentZiprasidone decreases cortisol excretion in healthy subjects.Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.Ziprasidone hydrocloride: what role in the management of schizophrenia?Profile of aripiprazole in the treatment of bipolar disorder in children and adolescentsPathophysiology and treatment of psychosis in Parkinson's disease: a review.Update on the role of antipsychotics in the treatment of Tourette syndrome.Efficacy and safety of aripiprazole in child and adolescent patientsEvidence review and clinical guidance for the use of ziprasidone in Canada.Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.Advances in diagnostic and treatment options in patients with fibromyalgia syndromeEmerging treatment options in bipolar disorder in adolescents: focus on ziprasidone.Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain.Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease.The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.
P2860
Q24564288-FA38A8DA-8CDE-4178-A6EA-B54236B30367Q24685521-5415B761-20C4-4981-BB1E-845E6486D625Q28972478-3EA89AEB-2BAA-4236-92E4-FE8707113623Q30498400-1CAF039C-2085-41D8-9164-5CD99E982314Q34042975-C3528701-C599-45E2-A515-A3BC4E104796Q34357931-43A1C678-3671-437B-B22E-6C4A13E3D4E1Q34600500-55A5D013-1CDF-4F01-94E9-77B06297E02CQ34610608-145F36AF-41B3-41B9-8627-4FEAB7A699D1Q35839717-A56036BE-5E14-488F-887D-F45C608734F5Q36075828-E99C56EE-CDE2-41A0-9B08-7C275B3623E3Q36588607-1A079345-7800-4E45-8123-C4943BFA54B9Q36700337-E71DCDDA-4517-4F9E-ADEB-B4F3F151C5CCQ36920020-7AFB7860-CB5A-407A-A80D-11FDD89B553BQ37358110-8F09697E-A8E9-400B-8DFE-F69D93091521Q37561314-E51B96E5-F085-460F-A846-1A101C17842DQ41111202-B57C6E3D-F034-4E51-9026-BAD76AB3551BQ41449158-D91AD0CE-191B-4A38-BA37-745535C7FFEFQ42227533-3C44D351-7A76-4F0D-9264-D4B2FE3B5DF7Q42990103-C7D2F04B-0AFE-44C1-AD5E-B2E0CA1A311E
P2860
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The psychopharmacology of zipr ...... al-world psychiatric practice.
@ast
The psychopharmacology of zipr ...... al-world psychiatric practice.
@en
type
label
The psychopharmacology of zipr ...... al-world psychiatric practice.
@ast
The psychopharmacology of zipr ...... al-world psychiatric practice.
@en
prefLabel
The psychopharmacology of zipr ...... al-world psychiatric practice.
@ast
The psychopharmacology of zipr ...... al-world psychiatric practice.
@en
P1476
The psychopharmacology of zipr ...... al-world psychiatric practice.
@en
P2093
Darius K Shayegan
Stephen M Stahl
P478
64 Suppl 19
P577
2003-01-01T00:00:00Z